Medindia

X

Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

Friday, January 8, 2010 Press Release J E 4
Advertisement


CARLSBAD, Calif., Jan. 6 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at J.P. Morgan's 28th Annual Healthcare Conference on Wednesday, January 13, 2010, at 9:30 a.m. PT at the Westin St. Francis in San Francisco.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 21 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
InSound(R) Medical Acquired by Sonova
S
Clarient CEO Ron Andrews to Present at J.P. Morgan...